glp-1 agonist drug list Savings: A Complete Guide for How to Save on Ozempic, Wegovy, and More The Boom in New Weight
Description
2023 doi: 10.1016/j.cjca.2025.03.011
The recent positive topline results from Eli Lilly and Company 's ATTAIN-MAINTAIN trial for orforglipron, however, signal a potential paradigm shift
Cost is a significant issue, one physician said
Some people may tolerate larger amounts without difficulty, whilst others experience symptoms at lower doses
Lean body mass remained mostly stable, so muscle loss was minimal and fat loss was maximized
